Seneca Therapeutics To Host a Key Opinion Leader Webinar on Seneca Valley Virus and TEM 8 On Wednesday, March 16th @ 2pmET

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), announced today that it will host a key opinion leader (KOL) webinar titled “Seneca Valley Virus and TEM8” on Wednesday, March 16, 2022 at 2:00pm Eastern Time.

The webinar will feature presentations from cancer researcher Mihnea Bostina, Ph.D., from the University of Otago and cancer clinician Aman Chauhan, M.D., from the University of Kentucky. Dr. Bostina will discuss the unique characteristics and exquisite solid tumor specificity of SVV-001 in the treatment of solid cancers. He will also discuss the mechanism of SVV receptor selectivity, specifically TEM8, an integrin expressed primarily on the surface of solid tumor cells. In multiple, well controlled clinical trials, TEM8 was shown to be an important adverse prognostic indicator of survival of patients with a variety of solid tumors. Dr. Chauhan will review three prior human clinical trials performed with intravenously delivered SVV-001 to patients having one of several solid cancer indications. He will also present new data on SVV’s profound ability to synergize with checkpoint inhibitors in animal models. Dr. Chauhan will discuss the Company’s upcoming Phase I/II randomized trial design in patients with neuroendocrine neoplasms that have SVV-001 sensitivity based on the SVV Companion Diagnostic.

Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics will give a brief presentation on the history of SVV-001. He will also discuss two new programs in development including the enablement of multiple intravenous administration with SVV and a significant pipeline of armed SVV constructs.

A live question-and-answer session will follow. To register for the event, please click here.

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products. Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.